Resolve Biosciences Appoints Erik Wiberg as Chief Financial Officer
13 September 2021 - - Germany-based Molecular Cartography specialist Resolve Biosciences has appointed Erik Wiberg as chief financial officer, the company said.

In this role, Wiberg will report to o-founder and CEO Jason T. Gammack and be responsible for the company's finance, legal, human resources, and administrative functions.

Wiberg brings more than 30 years of experience, including CFO roles at public and private firms in the medical device and biotechnology industries.

Prior to joining Resolve, he served as CFO at Reva Medical, a provider of bioresorbable polymer technologies for vascular applications.

He also held the CFO and vice president of Administration position at Gyros Protein Technologies AB, as well as senior finance leadership positions at Thermo Fisher Scientific, AlliedSignal, and the Chamberlain Group.

Wiberg holds a bachelor of science degree in mechanical engineering from the University of California, San Diego, as well as a master's degree in machine vision and optics and an MBA from the University of California, Los Angeles.

Scientists interested in learning more about the innovative Molecular Cartography services can contact the Resolve team.

Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.

The platform features the company's proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue.

The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease.

The technology has been under development since 2016 and is currently available through Resolve Biosciences' commercial service laboratory.

Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif.